Utilization of Extended-Interval, Fixed-Dosing of Durvalumab, Every 4 Weeks, in US Patients with Unresectable Stage III NSCLC Following Concurrent Chemoradiation

R. Haque, E. McGary, M. Yang, R. Liu, J. M. Suga, L. H. Chen, Z. Zhu, D. Simmons,K. Hsieh,I. Cotarla, L. Sakoda

JOURNAL OF THORACIC ONCOLOGY（2024）

Cited 0|Views2

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined